Sign In
Buy CDXS
$2.72
+0.0300 (+1.12%)
At Close: Jun 03, 2026
Hedge Funds Are Selling Codexis, Inc. (CDXS)
07:06pm, Monday, 22'nd Jun 2020
The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Ev
Codexis Announces the Election of New Directors at its Annual Meeting of Stockholders
08:05pm, Tuesday, 16'th Jun 2020
Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, announces the election of new independent directors, Alison Moore, Ph.D. and Stephen Dilly, MBBS,
Global Biocatalysis & Biocatalyst Market Trends, Forecast and Competitive Analysis to 2024 - ResearchAndMarkets.com
12:00am, Friday, 12'th Jun 2020
The
Edited Transcript of CDXS earnings conference call or presentation 7-May-20 8:30pm GMT
03:19pm, Tuesday, 02'nd Jun 2020
Q1 2020 Codexis Inc Earnings Call
Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets
08:06pm, Monday, 01'st Jun 2020Codexis and Alphazyme Partner to Offer Novel Enzymes to Life Science and Diagnostic Markets
08:05pm, Monday, 01'st Jun 2020
Codexis, Inc. (CDXS), a leading protein engineering company and developer of high-performance enzymes, and Alphazyme LLC, an emerging leader in the development and manufacture of nucleic acid metaboli
Bleichroeder LP Buys Altice USA Inc, Brunswick Corp, Haymaker Acquisition Corp II, Sells Arqule ...
12:00am, Thursday, 28'th May 2020Codexis to Participate in Two Virtual Investment Conferences
11:00am, Wednesday, 27'th May 2020
REDWOOD CITY, Calif., May 27, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will participate in two virtual investment.
Codexis to Participate in Two Virtual Investment Conferences
12:00am, Wednesday, 27'th May 2020Should Codexis Investors Prepare for Slower Growth?
11:31pm, Friday, 22'nd May 2020
The company's largest source of revenue will be affected by the pandemic, but there appears to be a silver lining.
HC Wainwright & Co. Reiterates Buy on Codexis, Lowers Price Target to $21
11:18am, Monday, 11'th May 2020Codexis to Present at the UBS Virtual Healthcare Conference
11:00am, Monday, 11'th May 2020
REDWOOD CITY, Calif., May 11, 2020 -- Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that management will present at the UBS Virtual Healthcare.
H.C. Wainwright Sticks to Their Buy Rating for Codexis
10:51am, Monday, 11'th May 2020
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Codexis (NASDAQ:CDXS) on Monday, setting a price target of $21, which is approximately 71.71% above the present share price of
Codexis to Present at the UBS Virtual Healthcare Conference
12:00am, Monday, 11'th May 2020Codexis(CDXS) Q1 2020 Earnings Call Transcript
05:30am, Saturday, 09'th May 2020
Ladies and gentlemen, thank you for standing by, and welcome to the first-quarter 2020 Codexis earnings conference call. This is Bruce Voss with LHA. Thank you all for participating in today's Codex
